eSense-Cancer: Adapting an Online Intervention for Sexual Health Concerns to Gynecologic Cancer
NCT06619769
Recruiting
Sexual health is a vital component of gynecologic cancer treatment and survivorship. Unfortunately, most gynecologic cancer survivors lack sufficient information about the impact of cancer on sexual health and treatment opportunities. This research aims to assess how well an adapted online health intervention meets the sexual health needs of gynecologic cancer survivors and to test the efficacy of the new platform. If successful, eSense-Cancer may increase access to treatment for gynecologic can... Read More
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
02/26/2025
Locations: University of British Columbia, Vancouver, British Columbia
Conditions: Gynecologic Cancers
Register for Updates
QEEG Brain Signature of Depression & Neuromodulation-induced Recovery
NCT06719427
Recruiting
This study aims to explore how repetitive transcranial magnetic stimulation (rTMS), a treatment for depression, affects brain function. Depression disrupts the brain's complex network or regions that regulate cognition, emotion, and behavior. rTMS targets these disruptions to restore network function. To measure these effects, researchers will use dry quantitative EEG (qEEG), a new technology that records brain electrical activity quickly (15 minutes compared to 1 hour for traditional EEG) witho... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/26/2025
Locations: Sunnybrook Health Sciences Centre, North York, Ontario +1 locations
Conditions: Major Depressive Diorder
Register for Updates
Amplatzer Amulet LAAO Vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: University Hospital - Univ. of Alabama at Birmingham (UAB), Birmingham, Alabama +131 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Longitudinal Study for Central Nervous System Vasculitis
NCT05734404
Recruiting
Primary central nervous system vasculitis (CNSV) is a potentially fatal, single-organ vasculitis that often involves a spectrum of neurologic complications, including strokes, cognitive and speech impairment, visual loss, dementia, and encephalopathy. The purpose of this study is to establish a research cohort to investigate the disease process, treatments, and patient outcomes in CNSV.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Cleveland Clinic, Cleveland, Ohio +4 locations
Conditions: Central Nervous System Vasculitis, CNS Vasculitis, CNSV, Vasculitis
Register for Updates
Behaviour Change for Cancer Survivors Trial
NCT06624930
Recruiting
This study will be a two-arm, multi-site RCT, to examine the effects of an entirely virtual, 6-month supervised PA program plus standard exercise counselling (PA+EC) versus a supervised PA plus motivationally-enhanced behavioral counselling (PA+BC) on moderate to vigorous physical activity (MVPA) in cancer survivors. A 6-month post intervention follow-up (T2) and 1-year post intervention follow-up (T3; 1-year follow-up from post-intervention) will take place after the intervention to address mai... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: University of British Columbia, Vancouver, British Columbia +1 locations
Conditions: Cancer, Exercise
Register for Updates
Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population with Obesity
NCT06690905
Recruiting
This study aims to evaluate the feasibility of an open randomized controlled study which would assess the proportion patients with obesity who will have a favorable pharmacodynamic parameter (i.e. fT\> 100% MIC) after 24 hours of piperacillin-tazobactam administered as a prolonged intermittent infusion compared to a standard infusion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Hôpital Charles- Le Moyne, Greenfield Park, Quebec
Conditions: Infections, Obesity and Obesity-related Medical Conditions
Register for Updates
Registry of Patients Living with Type 1 Diabetes
NCT03720197
Recruiting
A registry of individuals with type 1 diabetes open to all patients with type 1 diabetes living in Canada will be established. The objective of this registry will be to measure the frequency and the severity of episodes of hypoglycemia. Participants will be invited to answer questionnaires about the frequency of their hypoglycemic episodes, their fear about hypoglycemia, their symptoms of hypoglycemia, the factors in cause (insulin therapy, nutrition, exercise, etc.), etc. Participation to the... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/24/2025
Locations: Alberta Diabetes Institute, Edmonton, Alberta +6 locations
Conditions: Type 1 Diabetes Mellitus
Register for Updates
Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree
NCT06851546
Recruiting
The purpose of this study to optimize Selective Laser Trabeculoplasty (SLT) application when used in the management of open angle glaucoma (OAG)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota +1 locations
Conditions: Open Angle Glaucoma
Register for Updates
Safety and Effectiveness of Automated Insulin Delivery (AID) Systems in Physically Active Adults with Type 1 Diabetes
NCT05626725
Recruiting
Despite recent medical and technological advances, optimal glycemic control (time in range; TIR) and prevention of hypoglycemia remain significant challenges for people living with type 1 diabetes (T1DM). Automated insulin delivery systems (AIDs) combine an insulin pump coupled via an algorithm with a continuous glucose monitor (CGM), allowing constant adjustment of insulin doses according to blood glucose levels. Despite the significant improvement in blood glucose parameters and quality of lif... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec
Conditions: Type 1 Diabetes
Register for Updates
Glycemic Control and Osteohealth in Adults Living with Type 1 Diabetes
NCT06158503
Recruiting
Bone damage is frequently observed in type 1 diabetes, and hyperglycemia is associated with an increased risk of fracture. This pilot study in 25 people living with type 1 diabetes aims to determine whether the introduction of an automated insulin delivery (AID) system improves bone markers through rapide optimization of glycemic control. Measurements will be taken before the start of AID, 2 months and 4 months afterwards.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/24/2025
Locations: CHUM, Montréal, Quebec +1 locations
Conditions: Type 1 Diabetes
Register for Updates
Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium
NCT06285409
Recruiting
This study will investigate the effects of drugs called "uterotonics" that help with the contraction of the uterus after a baby is born. This uterine contraction is very important to stop the bleeding after delivery. An uncontracted uterine state is called "uterine atony", which can lead to an excessive amount of post-delivery bleeding. Carbetocin is an uterotonic drug that works well to prevent post-delivery bleeding. In some cases, carbetocin is not enough to contract the uterus, and ongoing b... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
02/24/2025
Locations: Mount Sinai Hospital, Toronto, Ontario
Conditions: Postpartum Hemorrhage
Register for Updates
Updating Preventive and Treatment Guidelines for Hypoglycemia in Individuals Living with Type 1 Diabetes
NCT06683391
Recruiting
The REMODAL trial is a randomized crossover study aiming to update treatment guidelines for mild hypoglycemia in people with Type 1 diabetes using continuous glucose monitoring (CGM) technology. The study will assess whether treating mild hypoglycemia proactively (at a glucose threshold of 5.0 mmol/L) with lower doses of carbohydrate (CHO) is more effective than the traditional reactive approach (treatment at \< 4.0 mmol/L). The goal is to reduce hypoglycemia frequency and improve quality of lif... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Institut de recherches cliniques de Montréal, Montreal, Quebec +1 locations
Conditions: Type 1 Diabetes
Register for Updates